Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine citrate maintenance dose and retinopathy of prematurity in very low birth weight infants
IRCT20210110049985N1Phase 2Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of caffeine in retinopathy of prematurity (ROP) (2 arms), sponsored by Babol University of Medical Sciences. Primary endpoint: Effect of caffeine citrate maintenance dose on retinopathy of prematurity. Started Jan 2021; status: completed.
02
Drugs
caffeine
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on IRCT20210110049985N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210110049985N1.